{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:06:11Z","timestamp":1789596371272,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate whether the administration of prophylactic methylergonovine in addition to oxytocin in patients undergoing intrapartum cesarean birth reduces the need for additional uterotonic agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>This was a single-center, placebo-controlled, randomized trial of patients undergoing intrapartum cesarean birth. Patients were randomly allocated to receive intravenous oxytocin 300 mL\/minute plus intramuscular methylergonovine 0.2 mg (1 mL) or intravenous oxytocin 300 mL\/minute plus intramuscular normal saline (1 mL). The primary outcome was the receipt of additional uterotonic agents. Secondary outcomes included surgeon assessment of uterine tone, incidence of postpartum hemorrhage, quantitative blood loss, and blood transfusion. To detect a twofold decrease in the need for additional uterotonic agents (assuming a 42% baseline) with a two-sided type 1 error of 5% and power of 80%, a sample size of 76 patients per group was required.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>From June 2019 through February 2021, 80 patients were randomized to receive methylergonovine plus oxytocin and 80 were randomized to receive to oxytocin alone. Significantly fewer patients who were allocated to the methylergonovine group received additional uterotonic agents (20% vs 55%, relative risk [RR] 0.4, 95% CI 0.2\u20130.6). Participants receiving methylergonovine were more likely to have satisfactory uterine tone (80% vs 41%, RR 1.9, 95% CI 1.5\u20132.6), lower incidence of postpartum hemorrhage (35% vs 59%, RR 0.6, 95% CI 0.4\u20130.9), lower mean quantitative blood loss (967 mL vs 1,315 mL; mean difference 348, 95% CI 124\u2013572), and a lower frequency of blood transfusion (5% vs 23%, RR 0.2, 95% CI 0.1\u20130.6).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>The administration of prophylactic methylergonovine in addition to oxytocin in patients undergoing intrapartum cesarean birth reduces the need for additional uterotonic agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT03904446.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000004857","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:02:18Z","timestamp":1657281738000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Patients Undergoing Intrapartum Cesarean Birth"],"prefix":"10.1097","volume":"140","author":[{"given":"Nicole","family":"Masse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Dexter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S2214-109X(14)70227-X","article-title":"Global causes of maternal death: a WHO systematic analysis","volume":"2","author":"Say","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R3-20250423","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12884-016-1217-0","article-title":"Risk factors for severe postpartum hemorrhage: a case-control study","volume":"17","author":"Nyfl\u00f8t","year":"2017","journal-title":"BMC Pregnancy Childbirth"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMra1513247","article-title":"Postpartum hemorrhage","volume":"384","author":"Bienstock","year":"2021","journal-title":"N Engl J Med"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1055\/s-0031-1280856","article-title":"Assessing preventability for obstetric hemorrhage","volume":"28","author":"Della Torre","year":"2011","journal-title":"Am J Perinatol"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijgo.2013.06.024","article-title":"New WHO recommendations on prevention and treatment of postpartum hemorrhage","volume":"123","author":"Tun\u00e7alp","year":"2013","journal-title":"Int J Gynaecol Obstet"},{"key":"R8-20250423","first-page":"36","article-title":"Uterotonic agents: an update","volume":"36","author":"Saljoughian","year":"2011","journal-title":"US Pharm"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ajog.2015.01.008","article-title":"Second-line uterotonics and the risk of hemorrhage-related morbidity","volume":"212","author":"Butwick","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1097\/AOG.0000000000002351","article-title":"Postpartum hemorrhage. Practice Bulletin No. 183. American College of Obstetricians and Gynecologists","volume":"130","year":"2017","journal-title":"Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1213\/ANE.0000000000000781","article-title":"The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study","volume":"121","author":"Lavoie","year":"2015","journal-title":"Anesth Analg"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s12630-010-9297-1","article-title":"Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing cesarean delivery","volume":"57","author":"George","year":"2010","journal-title":"Can J Anaesth"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/AOG.0000000000003564","article-title":"Quantitative blood loss in obstetric hemorrhage. ACOG Committee Opinion No. 794. American College of Obstetricians and Gynecologists","volume":"134","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/AOG.0000000000004288","article-title":"Prophylactic administration of uterotonics to prevent postpartum hemorrhage in women undergoing cesarean delivery for arrest of labor: a randomized controlled trial","volume":"137","author":"Balki","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"56.e1","DOI":"10.1016\/j.ajog.2010.08.023","article-title":"Oxytocin exposure during labor among women with postpartum hemorrhage secondary to uterine atony","volume":"204","author":"Grotegut","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"R17-20250423","first-page":"386","article-title":"Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a randomized controlled trial","volume":"98","author":"Munn","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R18-20250423","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/reprod\/120.1.91","article-title":"Loss of myometrial oxytocin receptors during oxytocin-induced and oxytocin-augmented labour","volume":"120","author":"Phaneuf","year":"2000","journal-title":"J Reprod Fertil"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1471-0528.2007.01658.x","article-title":"Oxytocin-ergometrine co-administration does not reduce blood loss at caesarean delivery for labour arrest","volume":"115","author":"Balki","year":"2008","journal-title":"BJOG"},{"key":"R20-20250423","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1213\/ANE.0000000000001765","article-title":"A Role for adrenergic receptors in the uterotonic effects of ergometrine in isolated human term nonlaboring myometrium","volume":"124","author":"Fanning","year":"2017","journal-title":"Anesth Analg"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"103207","DOI":"10.1016\/j.ijoa.2021.103207","article-title":"Refractory uterine atony: still a problem after all these years","volume":"48","author":"Balki","year":"2021","journal-title":"Int J Obstet Anesth"},{"key":"R22-20250423","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/AOG.0000000000003574","article-title":"Evaluation of risk-assessment tools for severe postpartum hemorrhage in women undergoing cesarean delivery","volume":"134","author":"Kawakita","year":"2019","journal-title":"Obstet Gynecol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T18:02:46Z","timestamp":1745431366000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000004857"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004857","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"2022-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}